The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Cardiff Oncology Inc shares valued at $673,750 were purchased by PACE GARY W on Jul 30 ’25. At $2.45 per share, PACE GARY W acquired 275,000 shares. The insider’s holdings grew to 1,330,676 shares worth approximately $3.15 million following the completion of this transaction.
Also, PACE GARY W purchased 15,000 shares, netting a total of over 36,750 in proceeds. Following the buying of shares at $2.45 each, the insider now holds 1,345,676 shares.
Before that, Levine James E. had added 2,752 shares to its account. In a trade valued at $14,905, the Chief Financial Officer bought Cardiff Oncology Inc shares for $5.42 each. Upon closing the transaction, the insider’s holdings increased to 2,752 shares, worth approximately $0.15 million.
As published in their initiating research note from Ladenburg Thalmann on July 08, 2025, Cardiff Oncology Inc [CRDF] has been a Buy and the price target has been revised to $19. Analysts at Jefferies started covering the stock with ‘”a Hold”‘ outlook in a report released in late June. As of September 06, 2024, Craig Hallum has initiated its “Buy” rating for CRDF. Earlier on January 05, 2022, William Blair initiated its rating. Their recommendation was “an Outperform” for CRDF stock.
Analyzing CRDF Stock Performance
On last trading session, Cardiff Oncology Inc [NASDAQ: CRDF] plunged -4.82% to $2.37. The stock’s lowest price that day was $2.31, but it reached a high of $2.485 in the same session. During the last five days, there has been a drop of approximately -42.75%. Over the course of the year, Cardiff Oncology Inc shares have jumped approximately 3.04%. Shares of the company reached a 52-week high of $4.99 on 02/21/25 and a 52-week low of $2.31 on 07/31/25.
Support And Resistance Levels for Cardiff Oncology Inc (CRDF)
According to the 24-hour chart, there is a support level at 2.29, which, if violated, would cause prices to drop to 2.21. In the upper region, resistance lies at 2.47. The next price resistance is at 2.56. RSI (Relative Strength Index) is 28.67 on the 14-day chart, showing oversold technical sentiment.
Is Cardiff Oncology Inc subject to short interest?
Stocks of Cardiff Oncology Inc saw a sharp rise in short interest on 2025-07-15 jumping by 1.61 million shares to 18.9 million. Data from Yahoo Finance shows that the short interest on 2025-06-13 was 17.29 million shares. A jump of 8.5% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 13.17 of the overall float, the days-to-cover ratio (short ratio) jumped to 13.17.
Which companies own the most shares of Cardiff Oncology Inc (CRDF)?
In spite of this, 1 analysts ranked Cardiff Oncology Inc stock as Buy at the end of 2025. On December 08, 2021, Robert W. Baird assigned a price target of “an Outperform” to the stock and initiated coverage with a $19.
